Lymphovascular Space Invasion Portends Poor Prognosis in Low-Risk Endometrial Cancer. Issue 7 (September 2015)

• Record Type: Journal Article
• Authors: dos Reis, Ricardo; Burzawa, Jennifer K.; Tsunoda, Audrey T.; Hosaka, Masayoshi; Frumovitz, Michael; Westin, Shannon N.; Munsell, Mark F.; Ramirez, Pedro T.
• Is Part Of: International journal of gynecological cancer. Volume 25:Issue 7(2015:Sep.)
• Publication Date: 2015-09
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000000490
• Languages: English
• ISSNs: 1048-891X

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <sec> <title>Objective</title> <p>The prognostic significance of lymphovascular space invasion (LVSI) in patients with early-stage endometrial cancer is not established. We sought to determine if LVSI status in patients with early-stage low-risk endometrial cancer correlates with recurrence and survival.</p> </sec> <sec> <title>Methods</title> <p>The records of all women who underwent hysterectomy for primary treatment of endometrial cancer from January 2006 through January 2011 at 1 academic institution were reviewed. Patients with grade 1 or 2 endometrioid histology, myometrial invasion less than 50%, and disease confined to the uterus (clinical International Federation of Obstetrics and Gynecology stage IA) were analyzed. Fisher exact test and the Wilcoxon rank-sum test were applied to compare patients with and without LVSI. Recurrence-free survival (RFS) and overall survival (OS) were calculated using the Kaplan-Meier method.</p> </sec> <sec> <title>Results</title> <p>Two hundred forty patients met the inclusion criteria. Forty (16.7%) had LVSI. Ninety-one patients (37.9%) underwent lymphadenectomy. Median tumor size was 30 mm in patients with and 26 mm in patients without LVSI (<italic>P</italic> = 0.150). Thirty patients (12.5%) received adjuvant therapy. Site of recurrence did not differ between patients with and without LVSI. Patients with LVSI were more likely to have myometrial invasion (<italic>P</italic> < 0.001), postoperative pathologic grade 2 disease (<italic>P</italic> < 0.001), to undergo lymphadenectomy (<italic>P</italic> = 0.049) and receive adjuvant therapy (<italic>P</italic> < 0.001). The 5-year cumulative incidence of recurrence was 3.8% in the no-LVSI group and 14.2% in the LVSI group (<italic>P</italic> = 0.053). The presence of LVSI was significantly associated with worse RFS (<italic>P</italic> = 0.002) and OS (<italic>P</italic> = 0.013).</p> </sec> <sec> <title>Conclusions</title> <p>Patients with low-risk endometrial cancer and LVSI have worse RFS and OS despite being more likely to undergo lymphadenectomy and adjuvant therapy.</p> </sec> </abstract>